Physician profile
Amanda E Hare
NPI 1245748029
$30,426.95
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $3,781 · 2023: $1,044 · 2024: $4,371 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $7,243 · Travel and Lodging: $3,482 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,331.25 |
| Food and Beverage | $7,243.24 |
| Travel and Lodging | $3,481.87 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,573.72 | 2024-2025 | |
| Abbott Laboratories | $6,910.62 | 2021-2025 | Infinity |
| Acadia Pharmaceuticals INC | $1,034.19 | 2023-2025 | Nuplazid |
| Mdd US Operations, LLC | $672.03 | 2022-2025 | Gocovri |
| Amneal Pharmaceuticals LLC | $391.19 | 2024-2025 | Crexont, Rytary |
| Tg Therapeutics, INC. | $369.23 | 2024-2025 | |
| Kyowa Kirin, INC. | $339.06 | 2021-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $216.55 | 2025 | Inbrija, Xeomin |
| Supernus Pharmaceuticals, INC. | $189.82 | 2025 | Qelbree |
| Lilly USA, LLC | $188.21 | 2024-2025 | Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $185.71 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $142.63 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $137.41 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $120.13 | 2024 | Voquezna |
| Cala Health, INC. | $86.38 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.37 | 2023-2024 | Hyqvia |
| Medtronic, INC. | $70.56 | 2022-2023 | Percept PC Brainsense, Intellis Adaptivestim |
| Genzyme Corporation | $62.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.22 | 2024-2025 | Cobenfy, Zeposia |
| Alexion Pharmaceuticals, INC. | $57.68 | 2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $50.60 | 2023-2024 | Austedo Xr, Austedo |
| Catalyst Pharmaceuticals, INC. | $48.42 | 2024-2025 | |
| Lundbeck LLC | $45.68 | 2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $44.59 | 2023-2024 | |
| Axsome Therapeutics, INC. | $40.90 | 2025 | Symbravo, Auvelity |
| Ucb, INC. | $38.21 | 2025 | Rystiggo |
| Neurocrine Biosciences, INC. | $37.48 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $32.94 | 2025 | |
| Boston Scientific Corporation | $31.37 | 2024 | Watchman Flx |
| Biogen, INC. | $29.86 | 2025 | Tysabri, Vumerity |
| Neurelis, INC. | $26.79 | 2025 | Valtoco |
| Argenx US, INC. | $26.16 | 2024 | Vyvgart Hytrulo |
| Pfizer INC. | $25.89 | 2025 | |
| Amgen INC. | $23.89 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $20.38 | 2024 | Wainua |
| Insightec,INC | $19.08 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.